Overview

Efficacy, Safety and Tolerability Study of APL-130277 for the Acute Treatment of OFF Episodes in Patients With Parkinson's Disease

Status:
Completed

Trial end date:
2017-12-11

Target enrollment:

Participant gender:

Summary

A 12-week, prospective, multi-center, randomized, double-blind, placebo controlled, Phase 3 study in L-Dopa responsive PD patients with motor fluctuations ("OFF" episodes), designed to determine the efficacy, safety and tolerability of APL-130277.

Phase:

Phase 3

Details

Lead Sponsor:

Sunovion

Treatments:

Apomorphine